An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.

Pancreatic cancer is resistant to conventional therapies, but cutting-edge research may improve survival rates and patient ...

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Bristol-Myers Squibb Co’s Profitability and Valuation Ratios Bristol-Myers Squibb Co’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 17.58% ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...